NASH PASS™ integrates three science-driven elements: a proprietary screening methodology, an IRB-approved clinical protocol, and a searchable NASH registry. The methodology at the foundation of the NASH PASS™ program was developed and fine-tuned over the last decade within ProSciento’s early phase metabolic CRU. It is now exported in a highly controlled manner at strategic clinical trial sites across the U.S.
The NASH PASS™ patient data registry is a powerful tool to improve enrollment for NAFLD and NASH clinical trials. The registry compiles real-time and longitudinal data of pre-screened patients ready for enrollment and pre-qualified sites ready for an expedited study launch. Because of the nature of the data, the NASH PASS™ registry is also an important instrument to enhance scientific knowledge of NAFLD and NASH disease progression and the utility of diagnostic and prognostic biomarkers.